Parkman Healthcare Partners LLC Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

Parkman Healthcare Partners LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 30.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,163 shares of the company’s stock after selling 12,221 shares during the period. Eli Lilly and Company comprises approximately 2.9% of Parkman Healthcare Partners LLC’s holdings, making the stock its 7th largest holding. Parkman Healthcare Partners LLC’s holdings in Eli Lilly and Company were worth $21,742,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in LLY. FPC Investment Advisory Inc. boosted its position in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after acquiring an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $50,000. Fiduciary Advisors Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $58,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company in the fourth quarter worth about $66,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 1.3%

Eli Lilly and Company stock opened at $745.86 on Wednesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The business’s 50-day simple moving average is $804.15 and its two-hundred day simple moving average is $808.91. The company has a market cap of $706.88 billion, a PE ratio of 63.69, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned $2.58 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. HSBC lowered shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,002.80.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.